» Articles » PMID: 36337063

The Gene Manipulation and Cellular Immunotherapy Combination in the Treatment of Cancer

Abstract

Context: The immune system is directly linked to the tumors, from tumor formation to the tumor's development and metastasis. So, the interest of scientists over the protective immunological mechanisms has increased and shown gifted strategy in cancer treatment.

Evidence Acquisition: Genetic engineering and cellular immunotherapy are two different advanced molecular mechanisms to modify the immune responses and genome. Gene manipulation is the bioengineering technology that allows vectors to transfer new genetic information into the target cells. Cellular immunotherapy is an excellent strategy that connects the body's immune system to fight cancer.

Results & Conclusions: This review described that combination of genetic engineering and cellular immunotherapy has brought the novel antitumor repressive molecules stopping the tumor tissue immune tolerance and significantly expanding cancer therapy's effectiveness. Usually, cell immunotherapy and genetic engineering are considered two independent processes, and, in this review, we believe them in combinations. Here, we review these two novel approaches, and they are both combinations in terms of technological advances and clinical experience.

Citing Articles

Deciphering the Role of Cancer Stem Cells: Drivers of Tumor Evolution, Therapeutic Resistance, and Precision Medicine Strategies.

El-Tanani M, Rabbani S, Satyam S, Rangraze I, Wali A, El-Tanani Y Cancers (Basel). 2025; 17(3).

PMID: 39941751 PMC: 11815874. DOI: 10.3390/cancers17030382.


Recent advances in various adeno-associated viruses (AAVs) as gene therapy agents in hepatocellular carcinoma.

Hadi M, Allela O, Jabari M, Jasoor A, Naderloo O, Yasamineh S Virol J. 2024; 21(1):17.

PMID: 38216938 PMC: 10785434. DOI: 10.1186/s12985-024-02286-1.

References
1.
Aghamir S, Heshmat R, Ebrahimi M, Ketabchi S, Parichehreh Dizaji S, Khatami F . The Impact Of Gene (SDH) Mutations In Renal Cell Carcinoma (RCC): A Systematic Review. Onco Targets Ther. 2019; 12:7929-7940. PMC: 6771773. DOI: 10.2147/OTT.S207460. View

2.
Durgeau A, Virk Y, Corgnac S, Mami-Chouaib F . Recent Advances in Targeting CD8 T-Cell Immunity for More Effective Cancer Immunotherapy. Front Immunol. 2018; 9:14. PMC: 5786548. DOI: 10.3389/fimmu.2018.00014. View

3.
Forget M, Tavera R, Haymaker C, Ramachandran R, Malu S, Zhang M . A Novel Method to Generate and Expand Clinical-Grade, Genetically Modified, Tumor-Infiltrating Lymphocytes. Front Immunol. 2017; 8:908. PMC: 5539190. DOI: 10.3389/fimmu.2017.00908. View

4.
Rosenberg S, Yannelli J, Yang J, Topalian S, Schwartzentruber D, Weber J . Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J Natl Cancer Inst. 1994; 86(15):1159-66. DOI: 10.1093/jnci/86.15.1159. View

5.
Waldman A, Fritz J, Lenardo M . A guide to cancer immunotherapy: from T cell basic science to clinical practice. Nat Rev Immunol. 2020; 20(11):651-668. PMC: 7238960. DOI: 10.1038/s41577-020-0306-5. View